Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04970056 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pancreatic Cancer Early Detection Consortium

Study acronym: PRECEDE
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 65 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Site contacts updated at 1 of 60 sitesv65
  2. Site details revised at 2 of 60 sitesv64
  3. Site contacts updated at 9 of 60 sitesv63
  4. Site contacts updated at 1 of 60 sitesv62
  5. Enrollment target: 10000 to 20000
    • Eligibility criteria expanded, about 58 words
    • Site details revised at 7 of 60 sites
    v61
Show 45 earlier versionsHide 45 earlier versions
  1. Site details revised at 1 of 60 sitesv60
  2. Site contacts updated at 1 of 60 sitesv59
  3. Site contacts updated at 1 of 60 sitesv58
  4. Site contacts updated at 1 of 60 sitesv57
  5. Study sites: 59 to 60
    • Study arms: 8 to 10
    v56
  6. Site details revised at 1 of 59 sitesv55
  7. Study sites: 58 to 59v54
  8. Study sites: 56 to 58v53
  9. Site contacts updated at 55 of 56 sitesv52
  10. Study sites: 55 to 56v51
  11. Study sites: 54 to 55
    • Eligibility criteria expanded, about 64 words
    • Study arms: 7 to 8
    v50
  12. Study sites: 53 to 54v49
  13. Site contacts updated at 1 of 53 sitesv48
  14. Study sites revised (53)v47
  15. Study sites revised (53)v46
  16. Study sites revised (53)v45
  17. Site contacts updated at 1 of 53 sitesv44
  18. Enrollment target: 8000 to 10000
    • Study sites: 52 to 53
    v43
  19. Site contacts updated at 1 of 52 sitesv42
  20. Site contacts updated at 1 of 52 sitesv41
  21. Study sites: 51 to 52v40
  22. Study sites: 52 to 51v39
  23. Site details revised at 2 of 52 sitesv38
  24. Study sites: 51 to 52v37
  25. Site details revised at 2 of 51 sitesv36
  26. Study sites: 50 to 51v35
  27. Site contacts updated at 1 of 50 sitesv34
  28. Site contacts updated at 3 of 50 sitesv33
  29. Site contacts updated at 1 of 50 sitesv32
  30. Study sites: 49 to 50v31
  31. Site contacts updated at 1 of 49 sitesv30
  32. Study sites: 48 to 49v29
  33. Site contacts updated at 1 of 48 sitesv28
  34. Study sites: 47 to 48v27
  35. Study sites: 46 to 47v26
  36. Study sites: 45 to 46v25
  37. Study sites: 44 to 45v24
  38. Study sites: 43 to 44v23
  39. Site contacts updated at 1 of 43 sitesv22
  40. Study sites: 42 to 43v21
  41. Study sites: 41 to 42v20
  42. Study sites: 40 to 41v19
  43. Study sites: 38 to 40v18
  44. Site contacts updated at 1 of 38 sitesv17
  45. Site details revised at 1 of 38 sitesv16
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.
Trial Details
NCT Number NCT04970056
Lead Sponsor Arbor Research Collaborative for Health
Conditions
(from sponsor)		 Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma, Genetic Predisposition
Related terms Genetic Predisposition to Disease, Pancreatic Cyst, Pancreatic Neoplasms
Enrollment 20,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov